Leerink Partners assumed coverage on shares of Stoke Therapeutics (NASDAQ:STOK – Free Report) in a research note issued to investors on Monday, StockNewsAPI reports. The firm issued an outperform rating and a $18.00 target price on the stock.
Other equities research analysts have also issued reports about the company. Wedbush reissued an outperform rating and set a $17.00 price objective on shares of Stoke Therapeutics in a research note on Thursday, July 11th. HC Wainwright reaffirmed a buy rating and issued a $35.00 target price on shares of Stoke Therapeutics in a research report on Wednesday, September 11th. Finally, Needham & Company LLC reaffirmed a buy rating and issued a $22.00 target price on shares of Stoke Therapeutics in a research report on Thursday, August 8th. One equities research analyst has rated the stock with a hold rating and seven have assigned a buy rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of Moderate Buy and a consensus target price of $20.83.
Check Out Our Latest Stock Report on Stoke Therapeutics
Stoke Therapeutics Price Performance
Stoke Therapeutics (NASDAQ:STOK – Get Free Report) last posted its earnings results on Wednesday, August 7th. The company reported ($0.46) EPS for the quarter, beating the consensus estimate of ($0.57) by $0.11. The firm had revenue of $4.83 million for the quarter, compared to analysts’ expectations of $3.33 million. Stoke Therapeutics had a negative return on equity of 57.89% and a negative net margin of 683.35%. Equities analysts anticipate that Stoke Therapeutics will post -2.1 EPS for the current year.
Insider Transactions at Stoke Therapeutics
In other news, major shareholder Skorpios Trust sold 1,937,500 shares of Stoke Therapeutics stock in a transaction dated Thursday, September 19th. The stock was sold at an average price of $14.05, for a total value of $27,221,875.00. Following the transaction, the insider now directly owns 8,906,181 shares in the company, valued at approximately $125,131,843.05. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. 11.30% of the stock is currently owned by corporate insiders.
Institutional Investors Weigh In On Stoke Therapeutics
A number of institutional investors have recently added to or reduced their stakes in the company. Healthcare of Ontario Pension Plan Trust Fund grew its position in Stoke Therapeutics by 426.1% during the second quarter. Healthcare of Ontario Pension Plan Trust Fund now owns 1,387,200 shares of the company’s stock worth $18,741,000 after buying an additional 1,123,500 shares in the last quarter. Lynx1 Capital Management LP grew its position in Stoke Therapeutics by 40.3% during the second quarter. Lynx1 Capital Management LP now owns 5,185,191 shares of the company’s stock worth $70,052,000 after buying an additional 1,488,371 shares in the last quarter. The Manufacturers Life Insurance Company grew its position in Stoke Therapeutics by 16.7% during the second quarter. The Manufacturers Life Insurance Company now owns 13,964 shares of the company’s stock worth $189,000 after buying an additional 1,994 shares in the last quarter. Millennium Management LLC grew its position in Stoke Therapeutics by 528.6% during the second quarter. Millennium Management LLC now owns 289,067 shares of the company’s stock worth $3,905,000 after buying an additional 243,083 shares in the last quarter. Finally, Marshall Wace LLP grew its position in Stoke Therapeutics by 550.1% during the second quarter. Marshall Wace LLP now owns 1,161,037 shares of the company’s stock worth $15,686,000 after buying an additional 982,451 shares in the last quarter.
Stoke Therapeutics Company Profile
Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.
Further Reading
- Five stocks we like better than Stoke Therapeutics
- 3 Small Caps With Big Return Potential
- Whirlpool’s High Dividend Yield Is Too Good to Pass Up
- Stock Ratings and Recommendations: Understanding Analyst Ratings
- Holiday Spending Boom Ahead: 3 BNPL Stocks Poised for Gains
- Profitably Trade Stocks at 52-Week Highs
- Boeing: A Perfect Storm of Trouble Is a Loaded Buying Opportunity
Receive News & Ratings for Stoke Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stoke Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.